BTAI: Upcoming Regulatory Milestones Will Drive Momentum Following Key Phase 3 Success

Analysts have increased their fair value price target for BioXcel Therapeutics from $19 to $23.75, citing improved revenue growth expectations, a higher profit margin forecast, and optimism following positive BXCL501 study results as well as expanded indications. Analyst Commentary Recent analyst updates reflect a mix of optimism and ongoing caution surrounding BioXcel Therapeutics following positive developments for BXCL501 and improving financial projections.

BioXcel Therapeutics’ consensus price target was revised downward due to significantly reduced revenue growth forecasts, partly offset by improved profit margins, resulting in a new fair value estimate of $19.00. What's in the News The pivotal Phase 3 SERENITY At-Home clinical trial of BXCL501 for the acute treatment of agitation in bipolar disorders or schizophrenia at home has completed patient visits, with topline data expected soon to support a supplemental New Drug Application for outpatient label expansion.

AnalystConsensusTarget has decreased revenue growth from 224.4% to 198.1%, increased profit margin from 10.5% to 16.8%, decreased future PE multiple from 39.9x to 29.9x and decreased shares outstanding growth rate from 0.3% to 0.1%.